EXTH-50. DEVELOPMENT OF INVESTIGATOR INITIATED CLINICAL TRIAL OF TERT-TARGETING THERAPY USING ERIBULIN MESYLATE IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Despite of recent intense investigations, no effective molecular targeting therapy has been successfully developed in patients with glioblastomas (GBMs). Approximately 60–80% of GBM harbor mutations in the promoter region of telomerase reverse transcriptase (TERT), which leads to its upregulation. I...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Takahashi, Masamichi, Miki, Shunichiro, Fukuoka, Kohei, Maida, Yoshiko, Hayashi, Mitsuhiro, Hamada, Akinobu, Nishikawa, Ryo, Nagane, Motoo, Maruyama, Takashi, Mukasa, Akitake, Arakawa, Yoshiki, Arita, Hideyuki, Kitamura, Natsuko, Yonemori, Kan, Tamura, Kenji, Masutomi, Kenkichi, Narita, Yoshitaka, Ichimura, Koichi
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2017
Soggetti:
Abstracts
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692632/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.342
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi